- Sensorion axes hearing loss program; Novartis' biomarker data in muscular dystrophyPlus, news about Imaavy. 👂 Sensorion selects one hearing loss program, axes another: The biotech is ending the development of SENS-501 for OTOF-related hearing loss following a “strategic revie…Endpoints · 1mo ago↗ source
- Camurus’ second CRL for acromegaly drug; Teva details workforce cutsPlus, news about a drug shortages report and Axplora: 🛑 Camurus has been hit with a second CRL: The rejection is for the drug CAM2029 in acromegaly due to problems at a third-party manufacturer.…Endpoints · 1mo ago↗ source
- Novartis RNA drug acquired in $12B Avidity deal notches a trial win<p>The data showed that del-brax, an “antisense oligonucleotide conjugate” being tested against a muscle-wasting disease, met its primary endpoint in a Phase 1/2 study.</p>